A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

Clinical trial NCT05128942 · TERMINATED

Trial details

NCT number: NCT05128942
Sponsor: Spruce Biosciences
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Congenital Adrenal Hyperplasia 21-OHD

Start date: 2021-12-10
Primary completion: 2025-01-31
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.